diabetes
NICE recommends Lilly’s long-acting Bydureon
October 18, 2011Sales and Marketing Bydureon, NICE, diabetes
NICE has recommended Eli Lilly’s long-acting diabetes drug Bydureon after the failure of oral treatments. Bydureon (exenatide) – a long-acting …
Russian diabetes market to grow to $1.7 billion
October 17, 2011Sales and Marketing Russia, diabetes
Russia’s diabetes market is set be worth $1.7 billion by 2015, according to a new report. Industry analysts Decision Resources’ …
Novo Nordisk’s Victoza launched in China
October 10, 2011Sales and Marketing Byetta, China, Victoza, diabetes
Novo Nordisk’s Victoza is now available in China, one of the fastest growing diabetes markets in the world. Victoza (liraglutide …
NHS ‘wasted’ £625 million on modern insulin
September 23, 2011Sales and Marketing diabetes, insulin
The NHS has wasted £625 million on modern insulin products over the last decade, according to a new report in …
Health secretary calls for global action on lifestyle conditions
September 21, 2011cardiovascular, diabetes, respiratory, smoking
Health secretary Andrew Lansley has urged governments across the world to be “bold and determined” in working together to tackle …
Boehringer’s Trajenta launched in the UK
September 20, 2011Sales and Marketing Boehringer, Trajenta, diabetes
Boehringer Ingelheim has launched its new diabetes drug Trajenta in the UK, with a price tag to match its rival …
Fresh scrutiny for new diabetes drugs
September 15, 2011Sales and Marketing Byetta, GLP-1, Januvia, Merck, Novo Nordisk, Victoza, diabetes
Merck’s Januvia and Lilly’s Byetta face renewed safety questions this week as the European Association for the Study of Diabetes …
Takeda moves potential first-in-class diabetes drug into phase III
September 12, 2011Research and Development, Sales and Marketing TAK-875, Takeda, diabetes
Takeda has moved its potential first-in-class diabetes candidate TAK-875 into phase III clinical trials. The company hopes TAK-875 will offer …
Boehringer-Lilly’s Trajenta wins European approval
August 26, 2011Sales and Marketing Tradjenta, Trajenta, diabetes
Boehringer Ingelheim and Eli Lilly’s new type II diabetes drug Trajenta has been approved Europe. The European Commission backed Trajenta …
Sharp increase in NHS diabetes prescribing costs
August 25, 2011Sales and Marketing GP prescribing, NHS, diabetes, prescribing
NHS prescribing for diabetes has risen sharply, largely driven by the disease’s growing prevalence in the UK. Spending rose 41% …
Afrezza could breathe new life into inhaled insulin market
August 15, 2011Research and Development, Sales and Marketing diabetes, inhaled insulin, insulin, research and development news
New trials for MannKind’s investigational inhaled insulin drug Afrezza have been given the go-ahead by the FDA, potentially breathing new …
European reprieve for Takeda’s Actos
July 22, 2011Sales and Marketing Actos, diabetes
Takeda’s Actos is likely to remain on the market in Europe but regulators want the diabetes drug to carry stronger …
Future of AZ-BMS diabetes drug in doubt
July 20, 2011Research and Development, Sales and Marketing AstraZeneca, BMS, dapagliflozin, diabetes, research and development news
A US advisory committee has rejected an investigational compound for type II diabetes sufferers, throwing its future into doubt. Dapagliflozin, …
Takeda forced to withdraw Actos in France
July 11, 2011Sales and Marketing Actos, Competact, Takeda, diabetes
Takeda has officially taken its diabetes drug Actos off the market in France at the request of the country’s medicines …
Lilly prepares late-stage pipeline boost
July 1, 2011Research and Development, Sales and Marketing autoimmune diseases, diabetes, lilly, neuroscience, oncology
Eli Lilly has highlighted diabetes, oncology, autoimmune diseases and neuroscience as key therapy areas within its growth strategy. Within these …
